TargetBeta
KAT7
lysine acetyltransferase 7 · also HBOA, HBO1, MYST2 · Zinc fingers C2H2C-type
2 programs in company-led studies act on KAT7, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| KAT6/KAT7 Inhibitor IDE574rule | IDEAYA Biosciences | phase 1 | 11 running | KAT6A, KAT6B | NCIt |
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 11 running | KAT6A, KAT6B | NCIt |
Conditions their studies are in
- Neoplasms, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 14, 2029KAT6/KAT7 Inhibitor PF-08032562 · Pfizer · phase 1 · NCT07318805
- Dec 31, 2029KAT6/KAT7 Inhibitor IDE574 · IDEAYA Biosciences · phase 1 · NCT07540572
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.